Stable patient outcomes after switching cryodevices with a fast warming protocol

April 20, 2026

Allison Davis, lab manager at Ovation Indianapolis, presented findings at PCRS that evaluate whether clinical outcomes hold when transitioning cryodevices under a 1-minute TS-only warming protocol. She shares her insights on what the data means for labs weighing similar decisions. 

A retrospective review from Ovation Indianapolis found no statistically significant differences in blastocyst survival or pregnancy outcomes after transitioning from the S-Cryolock to the cryo-Go vitrification device using a 1-minute TS-only warming protocol.

Why it matters: Fast warming protocols are increasingly common, but the suitability of cryodevices with these new protocols – and due diligence when switching between devices – requires further evaluation to protect clinical outcomes. 

This real-world dataset from 461 autologous FET cycles across two phases offers one lab’s structured comparison, and a replicable validation framework for labs considering similar transitions.

Allison Davis, lab manager at Ovation Indianapolis, and colleagues recently examined whether clinical outcomes were maintained when moving from the S-Cryolock to the cryo-Go device after already having validated and implemented the fast warming protocol.

“We did stress testing and many rounds of practice before deciding to switch to the cryo-Go. After switching the device, we kept a close eye on KPIs to track the performance of the new device,” she said.

Design: Retrospective review of all autologous FET cycles between March 3 and August 26, 2025, with reported clinical outcomes1.

  • Phase 1 (S-Cryolock): 251 cycles, 277 blastocysts warmed
  • Phase 2 (cryo-Go): 210 cycles, 227 blastocysts warmed
  • All blastocysts vitrified using standard ES/VS protocols with Irvine Scientific Vit Kit – Freeze NX; all warming in Vit Kit – Warm NX with TS-only fast warming

Results: Davis found that timing from warming to embryo transfer, percentage of eSET, and implementation of PGT testing were similar across phases. 

Further, no statistically significant differences were observed for measured clinical outcomes. 

MetricPhase 1 (S-Cryolock)Phase 2 (cryo-GO)p-value
Blastocyst survival99.3%100%.201
Positive beta hCG70.5%<72.9%.579
Gestational sac visualization (ultrasound)60.2%62.4%.625
Ongoing pregnancy rates (fetal cardiac activity)<54.6%60.0%.241

With clinical KPIs stable across both devices, Davis recommends shifting evaluation to operational factors that affect day-to-day execution of fast protocols:

  • Timing when performing vitrification steps
  • Ease and safety of handling the cryodevice
  • Minimal device volume and size to assist fast protocols rates needed for good embryo survival
  • Compatibility with your local SOPs, regulations, and warming media

“Any change should be done in a very controlled manner,” she advised. 

For Davis, controlled validation means that lab managers should create an implementation sequence that fosters trust and confidence.

Lower the stakes. Practice using donated or discard material to validate any change in warming procedure or device change. 

Build team familiarity before go-live. Becoming very familiar with a device or protocol leads to higher success when actually put into use in the patient population.

“Labs will have SOPs to follow when implementing new products or procedures, but there is no one single right way to accomplish change,” said Davis. “As long as you are careful and methodical with implementation, while tracking important KPIs and training, a successful transition can occur.”

No detriment to clinical outcomes was observed in this single-center retrospective review when transitioning between the two cryodevices studied. A TS-only fast warming protocol performed consistently across both phases. For labs evaluating cryodevice options, the data supports that a well-validated transition, when executed methodically, need not compromise patient outcomes.

Want more insights like this delivered to your inbox?

Allison Davis is a lab manager at Ovation Indianapolis. Her Nexpring Health-sponsored poster “Comparison of clinical patient outcomes between vitrification devices in autologous frozen embryo transfer cycles when using a fast warming protocol” was delivered at the 2026 Pacific Coast Reproductive Society Annual Meeting.